Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) shares hit a new 52-week low during mid-day trading on Thursday. The company traded as low as $13.61 and last traded at $13.59, with a volume of 1,086,425 shares trading hands. The stock had previously closed at $14.10.
Wall Street Analysts Forecast Growth
NRIX has been the topic of several research reports. Royal Bank Of Canada lowered their target price on Nurix Therapeutics from $36.00 to $35.00 and set an “outperform” rating on the stock in a report on Tuesday, October 13th. Morgan Stanley boosted their price objective on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th. UBS Group increased their price objective on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. HC Wainwright raised their price objective on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research note on Friday, October 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $34.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, October 13th. Fourteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Nurix Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $34.43.
View Our Latest Stock Analysis on NRIX
Nurix Therapeutics Stock Performance
The firm has a fifty day moving average of $22.56 and a 200 day moving average of $20.09. The firm has a market capitalization of $1.48 billion, a PE ratio of 5.91 and a beta of 1.80.
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $4.73 EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $5.33. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 49.34%. The business had revenue of $673.06 million for the quarter, compared to analysts’ expectations of $24.35 million. Research analysts forecast that Nurix Therapeutics, Inc. will post 1.14 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, Director Julia Gregory sold 22,583 shares of Nurix Therapeutics stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $23.40, for a total transaction of $528,442.20. Following the transaction, the director directly owned 10,750 shares of the company’s stock, valued at $251,550. The trade was a 67.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gwenn Hansen sold 3,957 shares of the firm’s stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $26.28, for a total transaction of $103,989.96. Following the transaction, the insider owned 123,452 shares of the company’s stock, valued at approximately $3,244,318.56. This trade represents a 3.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 38,499 shares of company stock valued at $893,645 in the last three months. 6.70% of the stock is currently owned by corporate insiders.
Institutional Trading of Nurix Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of NRIX. GAMMA Investing LLC lifted its position in shares of Nurix Therapeutics by 95.4% in the third quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock worth $30,000 after buying an additional 620 shares during the last quarter. Nykredit A S acquired a new stake in shares of Nurix Therapeutics in the second quarter worth $32,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Nurix Therapeutics in the second quarter worth $33,000. Fifth Third Bancorp lifted its stake in shares of Nurix Therapeutics by 613.8% in the third quarter. Fifth Third Bancorp now owns 1,556 shares of the company’s stock worth $37,000 after buying an additional 1,338 shares during the last quarter. Finally, KBC Group NV bought a new stake in shares of Nurix Therapeutics during the 1st quarter worth $34,000.
About Nurix Therapeutics
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California. Founded in 2009, it develops medicines that aim to treat cancer and other diseases by changing the levels of specific proteins inside cells. The company’s technology focuses on protein degradation, using the cell’s natural protein-disposal system to remove disease-related proteins. Nurix also researches ways to regulate protein activity through ubiquitin signaling, a process that helps control how proteins function and are broken down.
See Also
- Five stocks we like better than Nurix Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
